Shuttle Pharmaceuticals (SHPH) said late Thursday it filed a provisional US patent for prostate-specific membrane antigen ligand conjugates to treat prostrate cancer.
The patent, "PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy," could advance diagnostic and therapeutic programs for patients with metastatic castration-resistant prostate cancer, the company said.
PSMA is expressed on the surface of cancer cells, and ligands targeting the antigen are smaller and present potential advantages for more efficient drug delivery, according to a company statement.
Shares are up nearly 10% in after-hours activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。